Breaking News

Abzena Receives $10M Investment from Biospring Partners

New capital will allow Abzena to further accelerate its growth plans. Abzena drove 80% revenue growth and tripled GMP manufacturing capacity in 1H20.

By: Contract Pharma

Contract Pharma Staff

Abzena, a global partnership research organization providing discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), has announced a $10 million investment of growth capital from Biospring Partners, a New York based investment firm.  The new capital will allow Abzena to further accelerate its growth plans. Abzena drove 80% revenue growth and tripled GMP manufacturing capacity in 1H20. “The investment by Biospring Partners is further validation that the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters